Ventyx Biosciences, a San Diego-based clinical-stage biopharmaceutical company, develops small molecule therapeutics for autoimmune diseases with a pipeline including VTX002, VTX958, VTX2735, and VTX3232. The company went public on October 21, 2021, and employs 74 people.